The Janus kinase (JAK) inhibitor Rinvoq (upadacitinib) from AbbVie has a current indication for moderate to severe active rheumatoid arthritis for patients with an inadequate response or intolerance to the immunosuppressant methotrexate. Rinvoq is seeking expanded approval for the drug to treat moderate to severe atopic dermatitis (AD), which is a form of eczema. Earlier this…